Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
10.3971/j.issn.1000-8578.2021.21.0365
- VernacularTitle:PD-1/PD-L1抑制剂相关的内分泌紊乱及其治疗的研究进展
- Author:
Yanliang LAI
1
;
Yan GENG
;
Bingquan YANG
Author Information
1. Department of Endocrinology, Nanjing Lishui People's Hospital (Zhongda Hospital Lishui Branch, Southeast University), Nanjing 211200, China
- Publication Type:Research Article
- Keywords:
Immune checkpoint;
PD-1;
Immune-related adverse events;
Endocrine disorders
- From:
Cancer Research on Prevention and Treatment
2021;48(11):1035-1040
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint therapy is a new mode of tumor therapy. At present, many kinds of PD-1/PD-L1 inhibitors have been approved for clinical application on various tumors, such as malignant melanoma, lung cancer, bladder cancer, lymphoma, etc. However, with the gradual promotion and application in clinical practice, various immune-related adverse reactions caused by PD-1/PD-L1 inhibitors have attracted extensive attention. Especially in recent years, a number of adverse reactions related to endocrine gland injury have been reported. This paper reviews the research status and corresponding clinical treatment methods of endocrine gland related adverse reactions caused by PD-1/PD-L1 inhibitors.
